Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Left-sided ulcerative colitis.

Douglas B Haghighi1, Bret A Lashner

  • 1Department of Gastroenterology and Hepatology, Cleveland Clinic Foundation, 9500 Euclid Avenue, A30, Cleveland, OH 44195, USA. Haghigd@ccf.org

Gastroenterology Clinics of North America
|June 5, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Local Stem Cell Therapy for Crohn's Perianal Fistulae.

Inflammatory bowel diseases·2018
Same author

Conflicts of Interest in Clinical Practice Guidelines.

Inflammatory bowel diseases·2018
Same author

Corrigendum to "Low Body Mass Index Can Identify Majority of Osteoporotic Inflammatory Bowel Disease Patients Missed by Current Guidelines".

TheScientificWorldJournal·2017
Same author

Impact of Low Immunoglobulin G Levels on Disease Outcomes in Patients with Inflammatory Bowel Diseases.

Digestive diseases and sciences·2016
Same author

Implementation of Clinical Pharmacogenomics within a Large Health System: From Electronic Health Record Decision Support to Consultation Services.

Pharmacotherapy·2016
Same author

Autoimmune features are associated with chronic antibiotic-refractory pouchitis.

Inflammatory bowel diseases·2014
Same journal

Living Donor Intestinal and Liver Transplantation.

Gastroenterology clinics of North America·2026
Same journal

Living Abdominal Organ Donation: A Plan B That Saves Lives.

Gastroenterology clinics of North America·2026
Same journal

Long-Term Outcomes of Living Liver Donors.

Gastroenterology clinics of North America·2026
Same journal

Perioperative Management of Living Liver Donor Patients.

Gastroenterology clinics of North America·2026
Same journal

Living Donor Liver Transplantation for Colorectal Cancer Liver Metastasis.

Gastroenterology clinics of North America·2026
Same journal

Living Donor Liver Graft in Adult Populations: Donor Selection and Workup.

Gastroenterology clinics of North America·2026
See all related articles

Left-sided ulcerative colitis is a less extensive form of pancolitis, sharing similar characteristics. Treatment involves topical 5-aminosalicylic acid (5ASA) agents, with oral options for non-responders, though their superiority is debated.

Area of Science:

  • Gastroenterology
  • Inflammatory Bowel Disease Research
  • Colorectal Health

Background:

  • Left-sided ulcerative colitis is increasingly recognized not as a distinct condition, but as a manifestation of pancolitis with limited extent.
  • Epidemiologic and genetic profiles of left-sided ulcerative colitis are considered analogous to pancolitis.
  • Colorectal cancer risk appears correlated with the extent of colitis, emphasizing the importance of disease extent assessment.

Purpose of the Study:

  • To clarify the classification and characteristics of left-sided ulcerative colitis.
  • To review the treatment strategies for left-sided ulcerative colitis.
  • To discuss the ongoing debate regarding the efficacy of different oral 5-aminosalicylic acid (5ASA) formulations.

Main Methods:

Related Experiment Videos

  • Literature review of studies on ulcerative colitis classification and treatment.
  • Analysis of epidemiological and genetic data related to colitis extent.
  • Comparative review of topical and oral 5-aminosalicylic acid (5ASA) therapies.

    • Main Results:

    • Left-sided ulcerative colitis is best understood as a limited form of pancolitis.
    • Topical 5-aminosalicylic acid (5ASA) agents are the primary treatment for left-sided disease.
    • Oral 5ASA agents with varied delivery mechanisms are considered for refractory cases, but clinical superiority remains debated.

    Conclusions:

    • Left-sided ulcerative colitis is a spectrum of pancolitis, not a separate entity.
    • Treatment escalation for left-sided ulcerative colitis involves topical then oral 5-aminosalicylic acid (5ASA) agents.
    • Further research is needed to definitively establish the clinical superiority of oral 5-aminosalicylic acid (5ASA) formulations.